Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Journey Medical (DERM) EBT (2020 - 2025)

Journey Medical (DERM) has disclosed EBT for 6 consecutive years, with -$2.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT rose 3.14% year-over-year to -$2.3 million, compared with a TTM value of -$8.5 million through Sep 2025, up 53.09%, and an annual FY2024 reading of -$14.6 million, down 302.29% over the prior year.
  • EBT was -$2.3 million for Q3 2025 at Journey Medical, up from -$3.7 million in the prior quarter.
  • Across five years, EBT topped out at $16.9 million in Q3 2023 and bottomed at -$15.3 million in Q2 2021.
  • Average EBT over 5 years is -$5.3 million, with a median of -$4.1 million recorded in 2025.
  • The sharpest move saw EBT tumbled 27063.46% in 2021, then skyrocketed 267.67% in 2023.
  • Year by year, EBT stood at -$13.4 million in 2021, then rose by 20.77% to -$10.6 million in 2022, then surged by 81.02% to -$2.0 million in 2023, then skyrocketed by 178.43% to $1.6 million in 2024, then plummeted by 246.33% to -$2.3 million in 2025.
  • Business Quant data shows EBT for DERM at -$2.3 million in Q3 2025, -$3.7 million in Q2 2025, and -$4.1 million in Q1 2025.